| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PLA2G5 |
| Uniprot No | P39877 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-138aa |
| 氨基酸序列 | GLLDLKSMIEKVTGKNALTNYGFYGCYCGWGGRGTPKDGTDWCCWAHDHCYGRLEEKGCNIRTQSYKYRFAWGVVTCEPGPFCHVNLCACDRKLVYCLKRNLRSYNPQYQYFPNILCS |
| 预测分子量 | 15.6kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与PLA2G5重组蛋白相关的模拟参考文献示例(实际文献需根据具体研究核实)：
---
1. **文献名称**：Recombinant human PLA2G5 expression in insect cells: purification and functional characterization
**作者**：Smith A, et al.
**摘要**：报道了利用杆状病毒-昆虫细胞系统高效表达重组人PLA2G5蛋白的方法，通过亲和层析纯化获得高纯度蛋白，并验证其磷脂酶活性及在体外炎症模型中的促炎介质释放作用。
---
2. **文献名称**：Role of PLA2G5 in atherosclerosis: insights from recombinant protein studies
**作者**：Zhang L, et al.
**摘要**：研究重组PLA2G5蛋白在小鼠动脉粥样硬化模型中的作用，发现其通过水解氧化低密度脂蛋白(oxLDL)促进巨噬细胞泡沫化，提示PLA2G5可能成为心血管疾病的治疗靶点。
---
3. **文献名称**：Structural analysis of PLA2G5 using recombinant protein crystallography
**作者**：Tanaka K, et al.
**摘要**：通过重组表达人PLA2G5并进行X射线晶体学研究，解析其三维结构，揭示钙离子结合位点及底物结合域的关键氨基酸残基，为设计特异性抑制剂提供结构基础。
---
注：以上为模拟示例，实际文献需通过PubMed等数据库检索关键词(如“PLA2G5 recombinant”)获取。
Phospholipase A2 Group V (PLA2G5), a member of the secreted phospholipase A2 (sPLA2) family, is a calcium-dependent enzyme that hydrolyzes phospholipids at the sn-2 position to release free fatty acids, including arachidonic acid, and lysophospholipids. These products serve as precursors for bioactive lipid mediators involved in inflammation, immunity, and cell signaling. PLA2G5 is primarily expressed in immune cells, such as macrophages, and in tissues like the heart, placenta, and prostate. Its role extends beyond enzymatic activity; it interacts with cell surface receptors, including the M-type receptor (PLA2R1), modulating cellular responses in pathophysiological contexts.
Recombinant PLA2G5 protein is engineered using heterologous expression systems (e.g., mammalian cells, E. coli, or insect cells) to ensure proper folding and post-translational modifications. This enables researchers to study its structure-function relationships, substrate specificity, and regulatory mechanisms in vitro. PLA2G5 has been implicated in both pro- and anti-inflammatory processes, depending on the biological context. For example, it promotes atherosclerosis by enhancing lipoprotein modification and macrophage foam cell formation, yet it also exhibits anti-bacterial properties and may resolve inflammation by generating specialized pro-resolving lipid mediators.
Research on recombinant PLA2G5 has clinical relevance, particularly in cardiovascular diseases, cancer, and autoimmune disorders. Its dual roles highlight the complexity of lipid signaling networks and the need for targeted therapeutic strategies. Inhibitors or enhancers of PLA2G5 activity are being explored to modulate disease progression, though challenges remain in balancing its context-dependent effects. Overall, recombinant PLA2G5 serves as a critical tool for dissecting lipid-mediated pathways and developing precision therapies.
×
